GE acquires Biosafe Group

Biosafe, headquartered in the Lake Geneva region in Switzerland, markets products with closed fluid pathways, built-in traceability, and single-use consumables.
Biosafe, headquartered in the Lake Geneva region in Switzerland, with a global presence, has a 20 year track-record in automated cell processing and is a recognized leader in the field with reliable applications in bioprocessing, regenerative medicine and stem cell banking. Its proprietary products offer significant advantages over conventional processing tools, with closed fluid pathways, built-in traceability and single-use consumables. The strong strategic fit and complementary business models of GE Healthcare’s Life Sciences business and Biosafe combined with expanded capabilities in product development and commercial reach, will offer significant customer and ultimately patient benefits.
GE Healthcare acquired Biosafe Group, which supplies integrated cell bioprocessing systems for the cell therapy and regenerative medicine industry, for an undisclosed sum. The acquisition of Biosafe expands GE Healthcare’s end-to-end ecosystem of products, solutions, and services for its cell therapy customers and expands GE’s technology reach to a number of new cell and therapy types, according to Kieran Murphy, CEO Life Sciences, GE Healthcare.
General Electric’s health care unit aims to build a $1 billion business offering vital manufacturing tools for a coming wave of cell therapies, helped by the acquisition of a Swiss firm that doubles its presence in the field.
by: DEVIKA SHARMA